종양학용 AI 시장 : 컴포넌트별, 암 유형별, 용도별 - 세계 예측(-2036년)

AI in Oncology Market by Component (Software Solutions, Hardware, Services), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Others), and Application (Diagnostics, Treatment Planning, Drug Discovery & Development, Others) - Global Forecast to 2036

According to the research report titled, 'AI in Oncology Market by Component (Software Solutions, Hardware, Services), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Others), and Application (Diagnostics, Treatment Planning, Drug Discovery & Development, Others) - Global Forecast to 2036,' the global AI in oncology market is expected to reach approximately USD 49.53 billion by 2036 from USD 5.40 billion in 2026, at a CAGR of 24.8% during the forecast period (2026-2036).

The report provides an in-depth analysis of the global AI in oncology market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036. Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges.

The major factors driving the growth of the AI in oncology market include the intensifying global focus on precision medicine and the rapid expansion of intelligent diagnostic frameworks across diverse clinical ecosystems. Additionally, the rapid expansion of deep learning algorithms, increasing need for high-performance medical imaging, genomic analysis capabilities, and digital health integration are expected to create significant growth opportunities for players operating in the AI in oncology market.

Market Segmentation

The AI in oncology market is segmented by component (software solutions, hardware, services), cancer type (breast cancer, lung cancer, prostate cancer, others), application (diagnostics, treatment planning, drug discovery & development, others), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on Component

By component, the hardware segment holds the largest market share in 2026, primarily attributed to its essential role in supporting high-performance computing and data storage in hospital environments. These systems provide the computational infrastructure necessary for processing complex medical imaging datasets and enabling real-time diagnostic analysis. However, the software solutions segment is expected to grow at the fastest CAGR during the forecast period, driven by the increasing adoption of AI algorithms for clinical decision support, image analysis automation, and personalized treatment planning. The ability to deliver integrated solutions with proven clinical efficacy makes advanced software platforms highly attractive for healthcare institutions.

Based on Cancer Type

By cancer type, the breast cancer segment holds the largest market share in 2026, primarily due to its efficacy in handling high-volume screening data and providing scalable, predictive results for early intervention. The widespread adoption of mammography screening programs and the availability of large training datasets have accelerated AI algorithm development in this segment. The lung cancer segment is expected to witness significant growth during the forecast period, driven by the need for early detection capabilities, advanced imaging analysis, and treatment optimization. Prostate cancer and other cancer types represent emerging segments with growing adoption of AI-driven diagnostic and therapeutic approaches.

Based on Application

By application, the diagnostics segment holds the largest share of the overall market in 2026, due to its critical role in early cancer detection and clinical decision support. AI-powered diagnostic systems provide enhanced accuracy, reduced false positives, and improved patient outcomes through advanced image analysis and pattern recognition. The treatment planning segment is expected to grow at a significant CAGR during the forecast period, driven by the need for personalized treatment protocols and improved therapeutic outcomes. Drug discovery and development applications represent emerging segments with substantial growth potential as pharmaceutical companies increasingly leverage AI for accelerated drug candidate identification and clinical trial optimization.

Geographic Analysis

An in-depth geographic analysis of the industry provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) and the coverage of major countries in each region. In 2026, North America dominates the global AI in oncology market with the largest market share, primarily attributed to massive investments in AI research and development and the presence of leading technology innovators in the United States and Canada. Asia-Pacific is expected to witness the fastest growth during the forecast period, supported by aggressive digital transformation initiatives and rapid adoption of AI-driven clinical services in China, India, and Japan. Europe, Latin America, and the Middle East & Africa represent emerging markets with growing healthcare digitalization and increasing adoption of AI-powered oncology solutions.

Key Players

The key players operating in the global AI in oncology market are IBM Corporation, Microsoft Corporation, Google LLC, NVIDIA Corporation, Siemens Healthineers, Philips Healthcare, GE Healthcare, Varian (Siemens), Elekta AB, Tempus AI, Paige, Recursion Pharmaceuticals, Exscientia, PathAI, Ayasdi, and various other regional and emerging technology providers, among others.

Key Questions Answered in the Report-

• What is the current revenue generated by the AI in oncology market globally?
• At what rate is the global AI in oncology market demand projected to grow for the next 7-10 years?
• What are the historical market sizes and growth rates of the global AI in oncology market?
• What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
• Which segments in terms of component, cancer type, and application are expected to create major traction for the service providers in this market?
• What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the companies operating in the global AI in oncology market?
• Who are the major players in the global AI in oncology market? What are their specific product offerings in this market?
• What are the recent strategic developments in the global AI in oncology market? What are the impacts of these strategic developments on the market?

Scope of the Report:

AI in Oncology Market Assessment -- by Component

• Software Solutions
• Hardware
• Services

AI in Oncology Market Assessment -- by Cancer Type

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Others

AI in Oncology Market Assessment -- by Application

• Diagnostics
• Treatment Planning
• Drug Discovery & Development
• Others

AI in Oncology Market Assessment -- by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition
• 1.2. Market Scope
• 1.3. Research Methodology
• 1.4. Assumptions & Limitations

2. Executive Summary

3. Market Overview

• 3.1. Introduction
• 3.2. Market Dynamics
  • 3.2.1. Drivers
  • 3.2.2. Restraints
  • 3.2.3. Opportunities
  • 3.2.4. Challenges
• 3.3. Market Trends
  • 3.3.1. Proliferation of Generative AI and Multimodal Data Integration
  • 3.3.2. Innovation in Edge AI and Real-Time Clinical Decision Support
  • 3.3.3. Advancements in AI-Driven Drug Discovery
• 3.4. Regulatory Framework and Standards
• 3.5. Porter's Five Forces Analysis
• 3.6. PESTEL Analysis
• 3.7. Value Chain Analysis

4. Global AI in Oncology Market, by Component

• 4.1. Introduction
• 4.2. Software Solutions
  • 4.2.1. AI Platforms
  • 4.2.2. Cloud-based Solutions
• 4.3. Hardware
  • 4.3.1. Processors (GPUs, TPUs)
  • 4.3.2. Storage Devices
  • 4.3.3. Networking Systems
• 4.4. Services
  • 4.4.1. Professional Services
  • 4.4.2. Managed Services

5. Global AI in Oncology Market, by Cancer Type

• 5.1. Introduction
• 5.2. Breast Cancer
• 5.3. Lung Cancer
• 5.4. Prostate Cancer
• 5.5. Colorectal Cancer
• 5.6. Brain Tumor
• 5.7. Others

6. Global AI in Oncology Market, by Application

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Medical Imaging
  • 6.2.2. In-vitro Diagnostics
• 6.3. Treatment Planning
  • 6.3.1. Radiation Therapy
  • 6.3.2. Chemotherapy
  • 6.3.3. Immunotherapy
• 6.4. Drug Discovery & Development
• 6.5. Research & Clinical Trials
• 6.6. Others

7. Global AI in Oncology Market, by End User

• 7.1. Introduction
• 7.2. Hospitals & Diagnostic Centers
• 7.3. Pharmaceutical & Biotechnology Companies
• 7.4. Academic & Research Institutes
• 7.5. Others

8. Global AI in Oncology Market, by Geography

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. UK
  • 8.3.3. France
  • 8.3.4. Italy
  • 8.3.5. Spain
  • 8.3.6. Rest of Europe
• 8.4. Asia-Pacific
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. South Korea
  • 8.4.5. Australia
  • 8.4.6. Rest of Asia-Pacific
• 8.5. Latin America
  • 8.5.1. Brazil
  • 8.5.2. Mexico
  • 8.5.3. Argentina
  • 8.5.4. Chile
  • 8.5.5. Colombia
  • 8.5.6. Rest of Latin America
• 8.6. Middle East & Africa
  • 8.6.1. Saudi Arabia
  • 8.6.2. UAE
  • 8.6.3. South Africa
  • 8.6.4. Egypt
  • 8.6.5. Israel
  • 8.6.6. Rest of Middle East & Africa

9. Competitive Landscape

• 9.1. Introduction
• 9.2. Market Share Analysis
• 9.3. Competitive Dashboard
  • 9.3.1. Industry Leader
  • 9.3.2. Market Differentiators
  • 9.3.3. Vanguards
  • 9.3.4. Emerging Companies
• 9.4. Recent Strategic Developments

10. Company Profiles

• 10.1. Siemens Healthineers AG
• 10.2. GE HealthCare Technologies Inc.
• 10.3. Koninklijke Philips N.V.
• 10.4. NVIDIA Corporation
• 10.5. Intel Corporation
• 10.6. IBM Corporation
• 10.7. Google LLC
• 10.8. Microsoft Corporation
• 10.9. ConcertAI
• 10.10. PathAI
• 10.11. Azra AI
• 10.12. iCAD, Inc.

11. Appendix